13.77
-0.87 (-5.94%)
| Previous Close | 14.64 |
| Open | 14.47 |
| Volume | 970,719 |
| Avg. Volume (3M) | 1,666,740 |
| Market Cap | 1,436,472,704 |
| Price / Earnings (TTM) | 172.13 |
| Price / Sales | 17.23 |
| Price / Book | 5.73 |
| 52 Weeks Range | |
| Earnings Date | 9 May 2025 - 22 May 2025 |
| Profit Margin | 8.97% |
| Operating Margin (TTM) | 54.51% |
| Diluted EPS (TTM) | 0.080 |
| Quarterly Revenue Growth (YOY) | 4,900.00% |
| Total Debt/Equity (MRQ) | 27.04% |
| Current Ratio (MRQ) | 14.26 |
| Operating Cash Flow (TTM) | 13.55 M |
| Levered Free Cash Flow (TTM) | 8.96 M |
| Return on Assets (TTM) | -0.66% |
| Return on Equity (TTM) | 3.28% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | ARS Pharmaceuticals, Inc. | Bearish | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 0.88 |
|
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 22.97% |
| % Held by Institutions | 75.51% |
| 52 Weeks Range | ||
| Median | 30.00 (117.87%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Scotiabank | 07 Mar 2025 | 30.00 (117.86%) | Buy | 10.85 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |